Re: Phage therapy proof of concept

[Guest guest]

ASFY

I recall years ago a BBC2 Horizon programme about Russian research into Phages.

They were sampling sewer outlets to get sample of viruses they could use.

This was following a bit of a balloon of bacteria resistivity, and also in

increase in the invested cost of new antibiotic treatments.

Have never really heard much since about use of phages.

>

>

> PLoS One. <http://www.ncbi.nlm.nih.gov/pubmed/21347240> 2011 Feb

> 15;6(2):e16963.

> Pulmonary Bacteriophage Therapy on Pseudomonas aeruginosa Cystic

> Fibrosis Strains: First Steps Towards Treatment and Prevention.

> Morello E

> <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Morello%20E%22%5BAuthor%5D>

> , Saussereau E

> <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Saussereau%20E%22%5BAuthor%5\

> D> , Maura D

> <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Maura%20D%22%5BAuthor%5D> ,

> Huerre M

> <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Huerre%20M%22%5BAuthor%5D> ,

> Touqui L

> <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Touqui%20L%22%5BAuthor%5D> ,

> Debarbieux L

> <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Debarbieux%20L%22%5BAuthor%5\

> D> .

>

> Molecular Biology of the Gene in Extremophiles Unit, Department of

> Microbiology, Institut Pasteur, Paris, France.

> Abstract

> Multidrug-resistant bacteria are the cause of an increasing number of

> deadly pulmonary infections. Because there is currently a paucity of

> novel antibiotics, phage therapy-the use of specific viruses that infect

> bacteria-is now more frequently being considered as a potential

> treatment for bacterial infections. Using a mouse lung-infection model

> caused by a multidrug resistant Pseudomonas aeruginosa mucoid strain

> isolated from a cystic fibrosis patient, we evaluated bacteriophage

> treatments. New bacteriophages were isolated from environmental samples

> and characterized. Bacteria and bacteriophages were applied intranasally

> to the immunocompetent mice. Survival was monitored and bronchoalveolar

> fluids were analysed. Quantification of bacteria, bacteriophages,

> pro-inflammatory and cytotoxicity markers, as well as histology and

> immunohistochemistry analyses were performed. A curative treatment (one

> single dose) administrated 2 h after the onset of the infection allowed

> over 95% survival. A four-day preventive treatment (one single dose)

> resulted in a 100% survival. All of the parameters measured correlated

> with the efficacy of both curative and preventive bacteriophage

> treatments. We also showed that in vitro optimization of a bacteriophage

> towards a clinical strain improved both its efficacy on in vivo

> treatments and its host range on a panel of 20 P. aeruginosa cystic

> fibrosis strains. This work provides an incentive to develop clinical

> studies on pulmonary bacteriophage therapy to combat multidrug-resistant

> lung infections.

>